Drug Profile
AR 1010
Alternative Names: AR1010Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator AriBio
- Class Antibacterials; Eye disorder therapies; Quinolones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ophthalmic infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Ophthalmic-infections in Unknown (Ophthalmic, Drops)
- 23 Feb 2021 AR 1010 is still in phase I trial for Ophthalmic-infections in Unknown (Ophthalmic, Drops) (AriBio pipeline, February 2021)
- 01 Jun 2016 Phase-I clinical trials in Ophthalmic infections (Ophthalmic)